Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by in-depth plasma proteome profiling

Ross L. Prentice, Sophie Paczesny, Aaron Aragaki, Lynn M. Amon, Lin Chen, Sharon J. Pitteri, Martin McIntosh, Pei Wang, Tina Buson Busald, Judith Hsia, Rebecca D. Jackson, Jacques E. Rossouw, JoAnn E. Manson, Karen Johnson, Charles Eaton, Samir M. Hanash

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Background: Coronary heart disease (CHD) and stroke were key outcomes in the Women's Health Initiative (WHI) randomized trials of postmenopausal estrogen and estrogen plus progestin therapy. We recently reported a large number of changes in blood protein concentrations in the first year following randomization in these trials using an in-depth quantitative proteomics approach. However, even though many affected proteins are in pathways relevant to the observed clinical effects, the relationships of these proteins to CHD and stroke risk among postmenopausal women remains substantially unknown.Methods: The same in-depth proteomics platform was applied to plasma samples, obtained at enrollment in the WHI Observational Study, from 800 women who developed CHD and 800 women who developed stroke during cohort follow-up, and from 1-1 matched controls. A plasma pooling strategy, followed by extensive fractionation prior to mass spectrometry, was used to identify proteins related to disease incidence, and the overlap of these proteins with those affected by hormone therapy was examined. Replication studies, using enzyme-linked-immunosorbent assay (ELISA), were carried out in the WHI hormone therapy trial cohorts.Results: Case versus control concentration differences were suggested for 37 proteins (nominal P <0.05) for CHD, with three proteins, beta-2 microglobulin (B2M), alpha-1-acid glycoprotein 1 (ORM1), and insulin-like growth factor binding protein acid labile subunit (IGFALS) having a false discovery rate <0.05. Corresponding numbers for stroke were 47 proteins with nominal P <0.05, three of which, apolipoprotein A-II precursor (APOA2), peptidyl-prolyl isomerase A (PPIA), and insulin-like growth factor binding protein 4 (IGFBP4), have a false discovery rate <0.05. Other proteins involved in insulin-like growth factor signaling were also highly ranked. The associations of B2M with CHD (P <0.001) and IGFBP4 with stroke (P = 0.005) were confirmed using ELISA in replication studies, and changes in these proteins following the initiation of hormone therapy use were shown to have potential to help explain hormone therapy effects on those diseases.Conclusions: In-depth proteomic discovery analysis of prediagnostic plasma samples identified B2M and IGFBP4 as risk markers for CHD and stroke respectively, and provided a number of candidate markers of disease risk and candidate mediators of hormone therapy effects on CHD and stroke.Clinical Trials Registration: ClinicalTrials.gov identifier: NCT00000611.

Original languageEnglish (US)
Article number48
JournalGenome Medicine
Volume2
Issue number7
DOIs
StatePublished - Jul 28 2010
Externally publishedYes

Fingerprint

Proteome
Coronary Disease
Stroke
Insulin-Like Growth Factor Binding Protein 4
beta 2-Microglobulin
Proteins
Hormones
Women's Health
Proteomics
Estrogens
Therapeutics
Enzyme-Linked Immunosorbent Assay
Peptidylprolyl Isomerase
Apolipoprotein A-II
Orosomucoid
Somatomedins
Progestins
Random Allocation
Observational Studies
Blood Proteins

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics
  • Molecular Biology
  • Molecular Medicine

Cite this

Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by in-depth plasma proteome profiling. / Prentice, Ross L.; Paczesny, Sophie; Aragaki, Aaron; Amon, Lynn M.; Chen, Lin; Pitteri, Sharon J.; McIntosh, Martin; Wang, Pei; Buson Busald, Tina; Hsia, Judith; Jackson, Rebecca D.; Rossouw, Jacques E.; Manson, JoAnn E.; Johnson, Karen; Eaton, Charles; Hanash, Samir M.

In: Genome Medicine, Vol. 2, No. 7, 48, 28.07.2010.

Research output: Contribution to journalArticle

Prentice, RL, Paczesny, S, Aragaki, A, Amon, LM, Chen, L, Pitteri, SJ, McIntosh, M, Wang, P, Buson Busald, T, Hsia, J, Jackson, RD, Rossouw, JE, Manson, JE, Johnson, K, Eaton, C & Hanash, SM 2010, 'Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by in-depth plasma proteome profiling', Genome Medicine, vol. 2, no. 7, 48. https://doi.org/10.1186/gm169
Prentice, Ross L. ; Paczesny, Sophie ; Aragaki, Aaron ; Amon, Lynn M. ; Chen, Lin ; Pitteri, Sharon J. ; McIntosh, Martin ; Wang, Pei ; Buson Busald, Tina ; Hsia, Judith ; Jackson, Rebecca D. ; Rossouw, Jacques E. ; Manson, JoAnn E. ; Johnson, Karen ; Eaton, Charles ; Hanash, Samir M. / Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by in-depth plasma proteome profiling. In: Genome Medicine. 2010 ; Vol. 2, No. 7.
@article{c81c77a1c7e1455481b95a1b601328ed,
title = "Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by in-depth plasma proteome profiling",
abstract = "Background: Coronary heart disease (CHD) and stroke were key outcomes in the Women's Health Initiative (WHI) randomized trials of postmenopausal estrogen and estrogen plus progestin therapy. We recently reported a large number of changes in blood protein concentrations in the first year following randomization in these trials using an in-depth quantitative proteomics approach. However, even though many affected proteins are in pathways relevant to the observed clinical effects, the relationships of these proteins to CHD and stroke risk among postmenopausal women remains substantially unknown.Methods: The same in-depth proteomics platform was applied to plasma samples, obtained at enrollment in the WHI Observational Study, from 800 women who developed CHD and 800 women who developed stroke during cohort follow-up, and from 1-1 matched controls. A plasma pooling strategy, followed by extensive fractionation prior to mass spectrometry, was used to identify proteins related to disease incidence, and the overlap of these proteins with those affected by hormone therapy was examined. Replication studies, using enzyme-linked-immunosorbent assay (ELISA), were carried out in the WHI hormone therapy trial cohorts.Results: Case versus control concentration differences were suggested for 37 proteins (nominal P <0.05) for CHD, with three proteins, beta-2 microglobulin (B2M), alpha-1-acid glycoprotein 1 (ORM1), and insulin-like growth factor binding protein acid labile subunit (IGFALS) having a false discovery rate <0.05. Corresponding numbers for stroke were 47 proteins with nominal P <0.05, three of which, apolipoprotein A-II precursor (APOA2), peptidyl-prolyl isomerase A (PPIA), and insulin-like growth factor binding protein 4 (IGFBP4), have a false discovery rate <0.05. Other proteins involved in insulin-like growth factor signaling were also highly ranked. The associations of B2M with CHD (P <0.001) and IGFBP4 with stroke (P = 0.005) were confirmed using ELISA in replication studies, and changes in these proteins following the initiation of hormone therapy use were shown to have potential to help explain hormone therapy effects on those diseases.Conclusions: In-depth proteomic discovery analysis of prediagnostic plasma samples identified B2M and IGFBP4 as risk markers for CHD and stroke respectively, and provided a number of candidate markers of disease risk and candidate mediators of hormone therapy effects on CHD and stroke.Clinical Trials Registration: ClinicalTrials.gov identifier: NCT00000611.",
author = "Prentice, {Ross L.} and Sophie Paczesny and Aaron Aragaki and Amon, {Lynn M.} and Lin Chen and Pitteri, {Sharon J.} and Martin McIntosh and Pei Wang and {Buson Busald}, Tina and Judith Hsia and Jackson, {Rebecca D.} and Rossouw, {Jacques E.} and Manson, {JoAnn E.} and Karen Johnson and Charles Eaton and Hanash, {Samir M.}",
year = "2010",
month = "7",
day = "28",
doi = "10.1186/gm169",
language = "English (US)",
volume = "2",
journal = "Genome Medicine",
issn = "1756-994X",
publisher = "BioMed Central",
number = "7",

}

TY - JOUR

T1 - Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by in-depth plasma proteome profiling

AU - Prentice, Ross L.

AU - Paczesny, Sophie

AU - Aragaki, Aaron

AU - Amon, Lynn M.

AU - Chen, Lin

AU - Pitteri, Sharon J.

AU - McIntosh, Martin

AU - Wang, Pei

AU - Buson Busald, Tina

AU - Hsia, Judith

AU - Jackson, Rebecca D.

AU - Rossouw, Jacques E.

AU - Manson, JoAnn E.

AU - Johnson, Karen

AU - Eaton, Charles

AU - Hanash, Samir M.

PY - 2010/7/28

Y1 - 2010/7/28

N2 - Background: Coronary heart disease (CHD) and stroke were key outcomes in the Women's Health Initiative (WHI) randomized trials of postmenopausal estrogen and estrogen plus progestin therapy. We recently reported a large number of changes in blood protein concentrations in the first year following randomization in these trials using an in-depth quantitative proteomics approach. However, even though many affected proteins are in pathways relevant to the observed clinical effects, the relationships of these proteins to CHD and stroke risk among postmenopausal women remains substantially unknown.Methods: The same in-depth proteomics platform was applied to plasma samples, obtained at enrollment in the WHI Observational Study, from 800 women who developed CHD and 800 women who developed stroke during cohort follow-up, and from 1-1 matched controls. A plasma pooling strategy, followed by extensive fractionation prior to mass spectrometry, was used to identify proteins related to disease incidence, and the overlap of these proteins with those affected by hormone therapy was examined. Replication studies, using enzyme-linked-immunosorbent assay (ELISA), were carried out in the WHI hormone therapy trial cohorts.Results: Case versus control concentration differences were suggested for 37 proteins (nominal P <0.05) for CHD, with three proteins, beta-2 microglobulin (B2M), alpha-1-acid glycoprotein 1 (ORM1), and insulin-like growth factor binding protein acid labile subunit (IGFALS) having a false discovery rate <0.05. Corresponding numbers for stroke were 47 proteins with nominal P <0.05, three of which, apolipoprotein A-II precursor (APOA2), peptidyl-prolyl isomerase A (PPIA), and insulin-like growth factor binding protein 4 (IGFBP4), have a false discovery rate <0.05. Other proteins involved in insulin-like growth factor signaling were also highly ranked. The associations of B2M with CHD (P <0.001) and IGFBP4 with stroke (P = 0.005) were confirmed using ELISA in replication studies, and changes in these proteins following the initiation of hormone therapy use were shown to have potential to help explain hormone therapy effects on those diseases.Conclusions: In-depth proteomic discovery analysis of prediagnostic plasma samples identified B2M and IGFBP4 as risk markers for CHD and stroke respectively, and provided a number of candidate markers of disease risk and candidate mediators of hormone therapy effects on CHD and stroke.Clinical Trials Registration: ClinicalTrials.gov identifier: NCT00000611.

AB - Background: Coronary heart disease (CHD) and stroke were key outcomes in the Women's Health Initiative (WHI) randomized trials of postmenopausal estrogen and estrogen plus progestin therapy. We recently reported a large number of changes in blood protein concentrations in the first year following randomization in these trials using an in-depth quantitative proteomics approach. However, even though many affected proteins are in pathways relevant to the observed clinical effects, the relationships of these proteins to CHD and stroke risk among postmenopausal women remains substantially unknown.Methods: The same in-depth proteomics platform was applied to plasma samples, obtained at enrollment in the WHI Observational Study, from 800 women who developed CHD and 800 women who developed stroke during cohort follow-up, and from 1-1 matched controls. A plasma pooling strategy, followed by extensive fractionation prior to mass spectrometry, was used to identify proteins related to disease incidence, and the overlap of these proteins with those affected by hormone therapy was examined. Replication studies, using enzyme-linked-immunosorbent assay (ELISA), were carried out in the WHI hormone therapy trial cohorts.Results: Case versus control concentration differences were suggested for 37 proteins (nominal P <0.05) for CHD, with three proteins, beta-2 microglobulin (B2M), alpha-1-acid glycoprotein 1 (ORM1), and insulin-like growth factor binding protein acid labile subunit (IGFALS) having a false discovery rate <0.05. Corresponding numbers for stroke were 47 proteins with nominal P <0.05, three of which, apolipoprotein A-II precursor (APOA2), peptidyl-prolyl isomerase A (PPIA), and insulin-like growth factor binding protein 4 (IGFBP4), have a false discovery rate <0.05. Other proteins involved in insulin-like growth factor signaling were also highly ranked. The associations of B2M with CHD (P <0.001) and IGFBP4 with stroke (P = 0.005) were confirmed using ELISA in replication studies, and changes in these proteins following the initiation of hormone therapy use were shown to have potential to help explain hormone therapy effects on those diseases.Conclusions: In-depth proteomic discovery analysis of prediagnostic plasma samples identified B2M and IGFBP4 as risk markers for CHD and stroke respectively, and provided a number of candidate markers of disease risk and candidate mediators of hormone therapy effects on CHD and stroke.Clinical Trials Registration: ClinicalTrials.gov identifier: NCT00000611.

UR - http://www.scopus.com/inward/record.url?scp=78651305024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651305024&partnerID=8YFLogxK

U2 - 10.1186/gm169

DO - 10.1186/gm169

M3 - Article

VL - 2

JO - Genome Medicine

JF - Genome Medicine

SN - 1756-994X

IS - 7

M1 - 48

ER -